FDA Seeking Databases To Track Patient Drug Exposure To NMEs
FDA is seeking databases for postmarketing research that have the ability to track patient exposure to new molecular entities approved in the last five years.
You may also be interested in...
Off-label drug use in pediatric patients will be tracked under FDA contracts for longitudinal prescription data.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011